> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ConMed CEO Won't Discuss Strategic Action Rumor — But Says He Can See Why 'Somebody Would Be Attracted'
- URL: https://www.bullished.co/conmed-ceo-wont-discuss-strategic-action-rumor-but-says-he-can-see-why-somebody-would-be-9ebb2fc2/
- Published: 2026-10-28T21:46:19.000Z
- Updated: 2026-10-28T21:46:19.000Z
- Description: CEO Pat Beyer cited 6.7% organic constant currency growth and a sharper three-market focus after a JPMorgan analyst asked about strategic action.
- Author: Matteo Parrino
- Tags: Earnings, CNMD, Industry: Healthcare

ConMed CEO Pat Beyer declined to address a rumor about strategic action for the company on its [third-quarter earnings call](https://markets.ft.com/data/announce/full?dockey=600-202610011605BIZWIRE%5FUSPRX%5F%5F%5F%5F20261001%5FBW622217-1&ref=bullished.co) Wednesday, then added, "I can see why somebody would be attracted to ConMed." ConMed, which makes surgical devices used in orthopedics and general surgery, grew organic constant currency sales 6.7% in the quarter.

## A rumor, and a pointed answer

A JPMorgan analyst said ConMed had mentioned in some releases that it was evaluating strategic action and asked for the latest on interest. Beyer replied:

## The case Beyer made

Beyer pointed to the exit from the gastroenterology business and a refocus on three markets: minimally invasive surgery, smoke evacuation and orthopedic soft tissue repair. He named three products driving them: AirSeal, Buffalo Filter and BioBrace.

He called that step one, deciding where to play and how to win. Step two, he said, is refining a multi-year plan covering M&A actions, how to win, and how to maximize growth while optimizing profitability.

Third-quarter net revenue was [$335.6 million](https://seekingalpha.com/news/4659576-conmed-non-gaap-eps-of-104-beats-by-004-revenue-of-3356m-misses-by-065m?ref=bullished.co), down 0.7% as reported. Adjusted earnings were $1.04 per diluted share, above the high end of the company's expectations, against $1.08 a year earlier. The company now guides full-year adjusted earnings of $4.54 to $4.61 per share.

## Appetite for M&A, details in February

Later, CFO John Gallagher told a Jefferies analyst the company has "an appetite for looking at revenue growth accretive M&A opportunities." He said he will lay out 2027 capital allocation specifics on the fourth-quarter call.

Gallagher said the leverage ratio stood at 2.7 times on September 30, coming down and freeing up capacity, though interest expense is high and the company is weighing its debt stack. ConMed has repurchased about $49.9 million of stock in the first nine months of 2026 and anticipates about $62 million for the full year.

Gallagher said the specifics on 2027 capital allocation, M&A priorities included, come on the fourth-quarter call.

### Sources

- [CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026 – Company Announcement - FT.com](https://markets.ft.com/data/announce/full?dockey=600-202610011605BIZWIRE%5FUSPRX%5F%5F%5F%5F20261001%5FBW622217-1&ref=bullished.co) — Financial Times
- [Conmed: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/conmed-q3-earnings-snapshot-205624788.html?ref=bullished.co) — Associated Press
- [CONMED Non-GAAP EPS of $1.04 beats by $0.04, revenue of $335.6M misses by $0.65M (CNMD:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4659576-conmed-non-gaap-eps-of-104-beats-by-004-revenue-of-3356m-misses-by-065m?ref=bullished.co) — seekingalpha.com
- [Conmed: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/conmed-q3-earnings-snapshot/616-0e8023cb-a6dd-4b2a-a3bb-4f188ad19a4e?ref=bullished.co) — Associated Press

### More on CONMED

- [CONMED Keeps Buying Back Stock With $180 Million Drawn On Its Revolver And Convertible Notes Due In June 2027](https://www.bullished.co/conmed-keeps-buying-back-stock-with-180-million-drawn-on-its-revolver-and-convertible-9fcbb20e/)
- [CONMED Narrows Its 2026 Sales Range, Raises Profit Forecast As Margin Widens To 56.4%](https://www.bullished.co/conmed-narrows-its-2026-sales-range-raises-profit-forecast-as-margin-widens-to-56-4-e7b0f693/)

[All CONMED (CNMD) coverage →](https://www.bullished.co/tag/cnmd/)